Cullinan Therapeutics Inc.
CGEM · United States
Share price · CGEM
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CGEM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026-20.7%
- 2 Oct 2026+6.7%
- 24 Sep 2026-8.5%
- 23 Sep 2026-22.2%
Nothing announced by CGEM that day or the session before.
- 11 Aug 2026+7.4%
Nothing announced by CGEM that day or the session before.
- 22 Jun 2026+15.1%
Nothing announced by CGEM that day or the session before.
- 4 Jun 2026-5.1%
Nothing announced by CGEM that day or the session before.
- 26 May 2026+11.7%
- 12 May 2026+9.6%
Nothing announced by CGEM that day or the session before.
- 4 May 2026+14.2%
Nothing announced by CGEM that day or the session before.
Share of unusual movement by asset
For each asset, the share of CGEM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | BCMA x CD3Multispecific antibody | Multiple Myeloma | |
| Phase 3 | EGFRSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1/2 | FLT3, CD3Multispecific antibody | Acute Myeloid Leukemia | |
| Phase 1 | CD19 x CD3Multispecific antibody | Systemic Lupus ErythematosusRheumatoid Arthritis |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
2029 (3)
January 2029 (1)
What to watch
March 2029 (1)
What to watch
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $40M | $88M+ $201M short-term inv. | $49M-$43M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $44M | $79M+ $256M short-term inv. | —-$38M operating cash flow | report ↗ |
| 2026-Q1 | — | $42M | $75M+ $277M short-term inv. | —-$46M operating cash flow | report ↗ |
| 2025-Q3 | — | $42M | $103M+ $229M short-term inv. | $51M-$37M operating cash flow | report ↗ |
| 2025-Q2 | — | $61M | $73M+ $193M short-term inv. | $70M-$58M operating cash flow | report ↗ |
| 2025-Q1 | — | $41M | $77M+ $227M short-term inv. | $49M-$43M operating cash flow | report ↗ |
| 2024-Q3 | — | $36M | $102M+ $476M short-term inv. | $41M-$34M operating cash flow | report ↗ |
| 2024-Q2 | — | $36M | $115M+ $547M short-term inv. | $42M-$36M operating cash flow | report ↗ |
| 2024-Q1 | — | $31M | $74M+ $359M short-term inv. | $37M-$38M operating cash flow | report ↗ |
| 2023-Q3 | — | $34M | $65M+ $402M short-term inv. | $39M-$34M operating cash flow | report ↗ |
| 2023-Q2 | — | $27M | $142M+ $350M short-term inv. | $32M-$31M operating cash flow | report ↗ |
| 2023-Q1 | — | $52M | $122M+ $269M short-term inv. | $58M-$51M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $20M | $243M+ $333M short-term inv. | $25M-$54M operating cash flow | report ↗ |
| 2022-Q2 | $0 | $26M | $354M+ $257M short-term inv. | —-$25M operating cash flow | report ↗ |
| 2022-Q1 | $0 | $25M | $76M+ $239M short-term inv. | $12M-$22M operating cash flow | report ↗ |
| 2021-Q3 | $0 | $13M | $88M+ $233M short-term inv. | $17M-$11M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $187M | $88M+ $290M short-term inv. | $55M-$176M operating cash flow | report ↗ |
Cullinan Therapeutics did not disclose revenue for 2025. R&D expenses were $187.4M, up 31.1% YoY, and cash and investments totaled $439.0M as of December 31, 2025. The company reported a full-year net loss attributable to Cullinan of $219.88M, including a fourth-quarter net loss of $50.7M.
Management expects cash runway into 2029 under its current operating plan. Initial CLN-978 data in SLE and RA are planned for Q2 2026, repeat dosing data in RA for Q3 2026, and initial Sjögren’s disease data for Q4 2026, with initial velinotamig autoimmune data also expected in Q4 2026. An H2 2026 CLN-049 dose-escalation update is planned, dose-expansion cohorts are expected to begin in Q2 2026, and a frontline AML combination study is planned to start in Q4 2026. Partner Taiho completed the rolling NDA submission for zipalertinib and enrollment of the REZILIENT3 frontline study, with top-line results expected by year-end 2026; Cullinan is eligible for $30M and up to $100M in U.S. regulatory milestones, plus a 50/50 U.S. profit share.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $143M | $83M+ $316M short-term inv. | $42M-$145M operating cash flow | report ↗ |
| 2023-FY | — | $148M | $98M+ $369M short-term inv. | $38M-$134M operating cash flow | report ↗ |
| 2022-FY | $0 | $92M | $156M+ $311M short-term inv. | —-$127M operating cash flow | report ↗ |
| 2021-FY | $19M | $58M | $60M+ $231M short-term inv. | $16M-$43M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 29 sales ($2.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-05 | Michaelson Jennifer · Chief Scientific Officer | Option exercise | 3,805 | $4.30 | $16K | Form 4 |
| 2026-11-05 | Michaelson Jennifer · Chief Scientific Officer | Open-market sale | 4,000 | $12.36 | $49K | Form 4 |
| 2026-11-05 | Michaelson Jennifer · Chief Scientific Officer | Option exercise (derivative) | 3,805 | — | — | Form 4 |
| 2026-09-08 | Michaelson Jennifer · Chief Scientific Officer | Option exercise | 4,000 | $4.30 | $17K | Form 4 |
| 2026-09-08 | Michaelson Jennifer · Chief Scientific Officer | Open-market sale | 8,000 | $21.57 | $173K | Form 4 |
| 2026-09-08 | Michaelson Jennifer · Chief Scientific Officer | Option exercise (derivative) | 4,000 | — | — | Form 4 |
| 2026-08-13 | Michaelson Jennifer · Chief Scientific Officer | Option exercise | 30,000 | $4.30 | $129K | Form 4 |
| 2026-08-13 | Michaelson Jennifer · Chief Scientific Officer | Open-market sale | 30,000 | $20.26 | $608K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 173 reporting institutions held 65.6M shares ($899.2M, 101.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 8,963,500 | $127.4M |
| 2 | MPM BIOIMPACT LLC | 7,648,268 | $108.7M |
| 3 | BVF INC/IL | 5,750,683 | $81.7M |
| 4 | BlackRock, Inc. | 4,449,966 | $63.2M |
| 5 | Kynam Capital Management, LP | 3,114,132 | $44.3M |
| 6 | STATE STREET CORP | 2,544,115 | $36.2M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 2,483,034 | $35.3M |
| 8 | Blue Owl Capital Holdings LP | 1,909,764 | $27.1M |
| 9 | RTW INVESTMENTS, LP | 1,705,960 | $24.2M |
| 10 | Venrock Adviser, LLC | 1,379,965 | $19.6M |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 1,368,268 | $19.4M |
| 12 | Siren, L.L.C. | 1,193,410 | $17.0M |
| 13 | Nextech Invest, Ltd. | 1,141,145 | $16.2M |
| 14 | BOOTHBAY FUND MANAGEMENT, LLC | 1,112,803 | $15.8M |
| 15 | MARSHALL WACE, LLP | 1,049,581 | $14.9M |